Wuhan Healthgen Biotechnology Corp. (SHA:688765)

Market Cap	26.20B
Revenue (ttm)	28.39M +17.0%
Net Income	-154.40M
EPS	-0.57
Shares Out	357.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,579,100
Average Volume	2,794,241
Open	73.23
Previous Close	72.81
Day's Range	73.00 - 75.00
52-Week Range	68.68 - 132.03
Beta	n/a
RSI	41.30
Earnings Date	n/a

About SHA:688765

Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial growth factor, recombinant human keratinocyte growth factor, recombinant human...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 158
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688765

Financial Performance

In 2024, SHA:688765's revenue was 25.22 million, an increase of 3.92% compared to the previous year's 24.26 million. Losses were -151.37 million, -19.04% less than in 2023.